New stroke drug shows promise in early trial
NCT ID NCT07205328
First seen Nov 01, 2025 · Last updated Jun 16, 2026 · Updated 35 times
Summary
This study tests a new drug called MT200605 in 360 people who have had an acute ischemic stroke within the past 24 hours. The drug aims to protect brain cells and reduce damage from the stroke. Participants will receive either a high, medium, or low dose of the drug or a placebo, along with standard care. The main goal is to see if more people can recover to near-normal function (measured by a score of 0 or 1 on the modified Rankin Scale) three months after the stroke.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
BeiJing Tiantan Hospital
RECRUITINGBeijing, Beijing Municipality, 100070, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.